Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Early intensification of chemotherapy with high-dose cytarabine either in the postremission or remission induction phase has recently been shown to improve long-term relapse-free survival (RFS) in patients with acute myeloid leukemia (AML). Comparable results have been produced with the double induction strategy. The present trial evaluated the contribution of high-dose versus standard-dose cytarabine to this strategy. Between March 1985 and November 1992, 725 eligible patients 16 to 60 years of age with newly diagnosed primary AML entered the trial. Before treatment started, patients were randomized between two versions of double induction: 2 courses of standard-dose cytarabine (ara-C) with daunorubicin and 6-thioguanine (TAD) were compared with 1 course of TAD followed by high-dose cytarabine (3 g/m2 every 12 hours for 6 times) with mitoxantrone (HAM). Second courses started on day 21 before remission criteria were reached, regardless of the presence or absence of blast cells in the bone marrow. Patients in remission received consolidation by TAD and monthly maintenance with reduced TAD courses for 3 years. The complete remission (CR) rate in the TAD-TAD compared with the TAD-HAM arm was 65% versus 71% (not significant [NS]), and the early and hypoplastic death rate was 18% versus 14% (NS). The corresponding RFS after 5 years was 29% versus 35% (NS). An explorative analysis identified a subgroup of 286 patients with a poor prognosis representing 39% of the entire population; they included patients with more than 40% residual blasts in the day-16 bone marrow, patients with unfavorable karyotype, and those with high levels of serum lactate dehydrogenase. Their CR rate was 65% versus 49% (p =.004) in favor of TAD-HAM and was associated with a superior event-free survival (median, 7 v 3 months; 5 years, 17% v 12%; P =.012) and overall survival (median, 13 v 8 months; 5 years, 24% v 18%; P =.009). This suggests that the incorporation of high-dose cytarabine with mitoxantrone may contribute a specific benefit to poor-risk patients that, however, requires further substantiation. Double induction, followed by consolidation and maintenance, proved a safe and effective strategy and a new way of delivering early intensification treatment for AML.

[1]  F. Appelbaum,et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.

[2]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[3]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[4]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[5]  R. Gray,et al.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. , 1997, Blood.

[6]  M. Grever,et al.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.

[7]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[8]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[9]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[10]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[11]  M. Oken,et al.  Varying intensity of postremission therapy in acute myeloid leukemia. , 1992, Blood.

[12]  B. Christensen,et al.  Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. , 1991, Leukemia.

[13]  H. Preisler,et al.  Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. , 1987, Seminars in oncology.

[14]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[15]  D. Freidel,et al.  An interim report , 1986 .

[16]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Hortobagyi Mitomycin-C in breast cancer. , 1985, Seminars in oncology.

[18]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[19]  H. Lazarus,et al.  High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Mjaaland,et al.  Mitoxantrone in the treatment of relapsed and refractory acute leukemia. , 1985, Investigational new drugs.

[21]  E. Estey,et al.  Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.

[22]  J. White,et al.  Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. , 1985, Seminars in oncology.

[23]  R. Silver,et al.  Phase I-II trial of mitoxantrone in acute leukemia. , 1985, Cancer treatment reports.

[24]  M. Fey High-dose cytosine arabinoside therapy for refractory leukemia. , 1984, Blood.

[25]  J. Moore,et al.  Mitoxantrone in the treatment of relapsed and refractory acute leukemia. , 1984, Seminars in oncology.

[26]  J. Glick,et al.  High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Spurr,et al.  Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. , 1984, Blood.

[28]  E. Estey,et al.  Phase II trial of mitoxantrone in refractory acute leukemia. , 1983, Cancer treatment reports.

[29]  R. Willemze,et al.  High dose cytosine arabinoside in the management of refractory acute leukaemia. , 2009, Scandinavian journal of haematology.

[30]  M. Pfreundschuh,et al.  Multicentre study on intensified remission induction therapy for acute myeloid leukemia. , 1982, Leukemia research.

[31]  C. Bloomfield,et al.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.

[32]  T. L. Smith,et al.  Factors related to length of complete remission in adult acute leukemia , 1980, Cancer.

[33]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[34]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[35]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[36]  D. Cox Regression Models and Life-Tables , 1972 .

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .